293 related articles for article (PubMed ID: 31514488)
21. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract][Full Text] [Related]
22. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
[TBL] [Abstract][Full Text] [Related]
24. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
[TBL] [Abstract][Full Text] [Related]
25. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
26. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
27. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
28. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.
Alrifai D; Sarker D; Maher J
Immunopharmacol Immunotoxicol; 2016; 38(1):50-60. PubMed ID: 26473647
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.
Kasloff SB; Pizzuto MS; Silic-Benussi M; Pavone S; Ciminale V; Capua I
J Virol; 2014 Aug; 88(16):9321-34. PubMed ID: 24899201
[TBL] [Abstract][Full Text] [Related]
30. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
31. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
Front Immunol; 2022; 13():958960. PubMed ID: 35990619
[TBL] [Abstract][Full Text] [Related]
32. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
[TBL] [Abstract][Full Text] [Related]
33. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
[TBL] [Abstract][Full Text] [Related]
34. Engineered T cells for pancreatic cancer treatment.
Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ
J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625
[TBL] [Abstract][Full Text] [Related]
36. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
[TBL] [Abstract][Full Text] [Related]
37. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.
Smith TT; Moffett HF; Stephan SB; Opel CF; Dumigan AG; Jiang X; Pillarisetty VG; Pillai SPS; Wittrup KD; Stephan MT
J Clin Invest; 2017 Jun; 127(6):2176-2191. PubMed ID: 28436934
[TBL] [Abstract][Full Text] [Related]
38. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Beatty GL; O'Hara MH; Lacey SF; Torigian DA; Nazimuddin F; Chen F; Kulikovskaya IM; Soulen MC; McGarvey M; Nelson AM; Gladney WL; Levine BL; Melenhorst JJ; Plesa G; June CH
Gastroenterology; 2018 Jul; 155(1):29-32. PubMed ID: 29567081
[TBL] [Abstract][Full Text] [Related]
39. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
Cheng X; Zhao G; Zhao Y
Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526
[TBL] [Abstract][Full Text] [Related]
40. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
